Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F12 | P00748 | 12/20 | 0.48 |
| ▸ | F2 | P00734 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22492445 | 0.81 | F12 (0.45) | F12F2ALDH1A1HPGDKDM4E | |
| SCHEMBL19643629 | 0.78 | F12 (0.46) | F12F2KDM4EMAPT | |
| SCHEMBL19127839 | 0.78 | F12 (0.50) | F12F2 | |
| SCHEMBL24648912 | 0.77 | AR (0.40) | F12F2ALDH1A1HPGDKDM4E | |
| SCHEMBL22492635 | 0.77 | F12 (0.48) | F12F2KIF11 | |
| SCHEMBL22492379 | 0.77 | F12 (0.48) | F12ALDH1A1HPGDKDM4EMAPT | |
| SCHEMBL28453741 | 0.75 | F2 (0.38) | F12F2ALDH1A1HPGDKDM4E | |
| SCHEMBL22492483 | 0.75 | NPC1 (0.50) | F12F2ALDH1A1HPGDKDM4E | |
| SCHEMBL22492436 | 0.75 | F12 (0.49) | F12KDM4EHTTSMN1; SMN2 | |
| SCHEMBL19644387 | 0.75 | PTPN7 (0.40) | F12ALDH1A1HPGDKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3716972-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111670034-A | Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases | 洛克菲勒大学 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | F12 14/4885F2 6/4885ALDH1A1 1832/4885 |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | TFPI, TFPI2, SERPINC1 | F12 14/4885F2 6/4885ALDH1A1 1832/4885 |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | F12 14/4885F2 6/4885ALDH1A1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.